These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17469692)

  • 1. Treatment of moderate to severe Alzheimer's disease: rationale and trial design.
    Herrmann N
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S103-8. PubMed ID: 17469692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of memantine for the treatment of Alzheimer's disease.
    Matsunaga S; Kishi T; Nomura I; Sakuma K; Okuya M; Ikuta T; Iwata N
    Expert Opin Drug Saf; 2018 Oct; 17(10):1053-1061. PubMed ID: 30222469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatments for Alzheimer's disease.
    Jackson GA
    Nurs Times; 2014 Feb 26-Mar 4; 110(9):24-6. PubMed ID: 24754108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
    Zemek F; Drtinova L; Nepovimova E; Sepsova V; Korabecny J; Klimes J; Kuca K
    Expert Opin Drug Saf; 2014 Jun; 13(6):759-74. PubMed ID: 24845946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
    Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
    Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
    Farlow MR
    Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil: new preparation. Moderate efficacy in Alzheimer's disease.
    Prescrire Int; 1998 Oct; 7(37):146-7. PubMed ID: 10915420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
    Jones RW
    Int J Geriatr Psychiatry; 2010 Jun; 25(6):547-53. PubMed ID: 20049770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
    Calhoun A; King C; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
    Schölzel-Dorenbos CJ;
    Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.